This study is a multi-centre randomized controlled, open label, phase II trial for patients with de-novo GBM.
Eligible patients will be randomized between arm A and arm B:
Arm A (standard): Radiotherapy and chemotherapy according to standard protocol for newly diagnosed GBM. This consists of 30